Cartalax

AED tripeptide bioregulatorHealing/Recovery

Evidence grade

DResearch/compounded/adjunct (no established FDA indication)

Cardiovascular · 0–5 · separate axis

Read first · not dosing instructions

Educational and research reference only. Not medical advice, not a recommendation, and not dosing instructions for any person. Figures are reported from the cited source and may be wrong or out of date. Research peptides are not approved for human use. Adults 18+. Consult a licensed physician before any decision about your health.

PurposeHealing / Connective tissue

MechanismAla-Glu-Asp tripeptide from the Khavinson bioregulator family, studied for cartilage and connective-tissue signalling.

EffectsStudied for cartilage and connective tissue. Evidence is preclinical plus one small unregistered human study.

DosingNo human dose established.

Bottom lineRussian bioregulator literature and community dosing; no Western clinical validation.

Not a dose · what the literature contains instead

Community protocols run 1–2 mg/day subcutaneously or 10–20 mg/day orally in 10–20 day cycles, two to three times a year. Those figures come from user practice, not from a trial.

Batches on filenone

No tested batches on file.

Read with

The library records no pairings for this entry.

Cautions & interactions

One small unregistered human study (n=29, knee osteoarthritis) and preclinical work. No validated clinical use, and essentially no independent Western trial data.

No interaction data published.

CV 1 of 5 — No cardiovascular data.